Funding Decisions


Translation Acceleration Grants (TAG2)

September 26, 2014 - Prostate Cancer Canada (PCC) is pleased to announce the results of the recent TAG2 competition: Novel Therapeutics for Advanced Disease. These grants are for groups studying novel therapeutics and treatment options for metastatic and castrate-resistant prostate cancer; the projects are aimed at eliminating advanced disease from affected men.

Two grants have been funded; this represents a total commitment of $2,840,430. Each grant is for three years starting October 1, 2014.
 

Prostate Cancer Canada Translation Acceleration Grant
Principal Investigator Institution Project Title Funded Amount
Paul Rennie University of British Columbia Pre-clinical development of the next-generation anti-androgens for the treatment of drug-resistant and advanced prostate cancer $1,463,090
 


 





 

Movember Translation Acceleration Grant
Principal Investigator Institution Project Title Funded Amount
Tak W. Mak University Health Network Clinical and translational development of novel mitotic kinase inhibitors, CFI-400945 and CFI-402257, in castrate refractory prostate cancer $1,377,340





Movember Discovery Grants Announced

June 5, 2014 - Prostate Cancer Canada and Movember are proud to announce the recipients of the 2014 Movember Discovery Grants.

The applications were reviewed by four panels encompassing biology of prostate cancer, early detection of prostate cancer, experimental therapeutics and clinical and population health. Fifty-one experts in all areas were recruited nation-wide and internationally to review the applications. Over two days in May, the four panels, scientific experts along with eight community representatives, met to discuss and rank the applications.

Twenty-six grants have been funded; this represents a total investment of $4,949,896. Each grant is for two years starting July 1, 2014.

Principal Investigator Institution Project Title Funded Amount
Khalid Al-Nedawi McMaster University Regulation of androgen receptor through microvesicles $200,000
Juan Ausio University of Victoria Examining the interplay between H2A.Z and EZH2 in androgen receptor dependent and independent signalling in prostate cancer $185,842
Bharati Bapat Lunenfeld-Tannenbaum Research Institute, University Health Network, University of Toronto Deciphering DNA methylome in metastatic prostate cancer $185,900
Peter Black University of British Columbia Circulating tumour cells for risk stratification in men with localized prostate cancer $182,800
Rodney Breau The Ottawa Hospital Improving quality of prostate cancer surgery by providing performance feedback to surgeons: a pilot study $194,777
Warren Chan University of Toronto Designing controlled release DNA-based drug delivery systems $187,000
Kim Chi University of British Columbia Genomic profiling of circulating tumour DNA (ctDNA) as a predictive biomarker for patients with castration resistant prostate cancer (CRPC) $199,300
Vincent Fradet Université Laval Epigenomic control of prostatic inflammation $198,000
Imed Gallouzi McGill University Elucidation of regulatory posttranscriptional mechanisms modulating STAT3 expression during prostate cancer-induced cachexia (muscle atrophy) $194,000
Fernand Gobeil Université de Sherbrooke Inducible kinin B1 receptors as prostate cancer theranostic targets $200,000
Stephane Gobeil Université Laval Identification of new metastasis suppressor genes in prostate cancer $199,772
S.M. Mansour Haeryfar Western University NKT cell-based adjuvant immunotherapy of prostate cancer $188,068
Gerald Krystal British Columbia Cancer Agency Generation of mesenchymal stromal cells infected with oncolytic herpes viruses expressing immune modulators to treat prostate cancer $200,000
Hon Leong Western University Developing a liquid biopsy format of Gleason scoring for prostate cancer prognostication $180,014
Shawn Li Western University Therapeutic potential of targeting SET7/9 induced methylation of DNA-PKcs in androgen-resistant prostate cancer $187,000
Andrew Loblaw Odette Cancer Centre, Sunnybrook Health Sciences Centre Single fraction HDR prostatic boost in the context of pelvic lymph node SABR (5 fractions) for high risk prostate cancer $159,650
Salaheddin Mahmud University of Manitoba The effect of antipsychotic medications on the incidence and aggressiveness of prostate cancer: a population based study $153,462
Naomi Matsuura University of Toronto Nanoscale oxygen transport carriers for radiosensitization of prostate tumours $197,656
Andrew Matthew Princess Margaret Cancer Centre A randomized trial of conventional versus advanced pelvic floor exercises to treat urinary incontinence following radical prostatectomy $158,291
Donald Poirier Université Laval An outstanding accumulation of a 17-beta-hydroxysteroid dehydrogenase type 3 (17b-HSD3) inhibitor in prostate cancer tumour opens the door to a specific treatment and imaging of prostate cancer using a radiolabeled 17b-HSD3 inhibitor $199,944
Rithwik Ramachandran University of Calgary Molecular regulation of TRPM8 in prostate cancer $199,735
Gurmit Singh McMaster University Prostate cancer-induced depression $198,685
Jose Teodoro McGill University Role of the Pro-Renin receptor in the progression and diagnosis of prostate cancer $200,000
Yuzhuo Wang University of British Columbia Identification of genes involved in development and progression of neuroendocrine prostate cancer $200,000
Xiao Yu Wu University of Toronto Hypoxia-modulating nanoparticles for enhancing radiation response of inoperable advanced prostate cancer $200,000
Alexandre Zlotta Mount Sinai Hospital Advancing precision medicine for prostate cancer through transcriptomics $200,000
Total: $4,949,896

Movember Team Grant Announced

June 5, 2014 - Prostate Cancer Canada and Movember are proud to announce the recipient of the 2014 Movember Team Grant.

This year, nine full applications were received. We sought and achieved a broad range of expertise from a team of international reviewers. The applications were submitted to a two-stage review process; an initial review identified a short list of applicant teams to invite to a Reverse Site Visit in Toronto.

This represents a total investment of $4,995,400 over five years starting July 1, 2014.

Program Director and Principal Investigator Institution Program Title Funded Amount
John Bartlett Ontario Institute for Cancer Research
Toronto, Ontario
The prostate cancer program project in rapid development of novel diagnostic markers for early prostate cancer (PRONTO) $4,995,400
Team Members:   Institutions:
David Berman 
Co-Principal Investigator 
 Queen's University
 Kingston, Ontario
Ralph Buttyan 
Co-Principal Investigator 
 University of British Columbia
 Vancouver, British Columbia
Craig Earle 
Co-Principal Investigator 
 Institute for Clinical Evaluative Studies
 Toronto, Ontario
Andrew Loblaw 
Co-Principal Investigator 
 Sunnybrook Health Sciences Centre
 Toronto, Ontario
Glenn Bauman 
Co-Investigator 
 London Health Sciences Centre
 London, Ontario
Paul Boutros 
Co-Investigator 
 Ontario Institute for Cancer Research
 Toronto, Ontario
Antonio Finelli 
Co-Investigator 
 Princess Margaret Cancer Centre
 Toronto, Ontario
Jacques Lapointe 
Co-Investigator 
 McGill University
 Montreal, Quebec
Paul Park 
Co-Investigator 
 Kingston General Hospital
 Kingston, Ontario
Eileen Rakovitch 
Co-Investigator 
 Sunnybrook Health Sciences Centre
 Toronto, Ontario
Refik Saskin 
Co-Investigator 
 Institute for Clinical Evaluative Studies
 Toronto, Ontario
Axel Thomson 
Co-Investigator 
 McGill University
 Montreal, Quebec
Theodorus van der Kwast 
Co-Investigator 
 Toronto General Hospital
 Toronto, Ontario
Vasundara Venkateswaran 
Co-Investigator 
 Sunnybrook Health Sciences Centre
 Toronto, Ontario


Movember Translation Acceleration Grants (TAG)

March 26, 2014 - Prostate Cancer Canada (PCC) is pleased to announce of the results of the recent Movember TAG competition. These grants are for groups developing and validating methods to specifically and accurately distinguish between aggressive prostate cancers that need to be treated as opposed to more indolent forms.   

Three grants have been funded; this represents a total commitment of $4,484,864. Each grant is for three years starting April 1, 2014.

This opportunity is proudly funded by the Movember Foundation.

Principal Investigator Institution Project Title Funded Amount
Bharati Bapat Lunenfeld-Tannenbaum Research Institute
Toronto, ON
Moving beyond discovery: validation of an integrated biomarker panel for detection of aggressive prostate cancer $1,500,000
Robert Day Université de Sherbrooke, Sherbrooke, QC Clinical validation of PACE4 for an improved diagnosis of prostate cancer $1,492,000
John Lewis University of Alberta
Edmonton, AB
Blood based detection of the migration switch in prostate cancer to predict metastatic disease $1,492,864
Total $4,484,864


Rising Star Recipients Announced

December 3, 2013 - Prostate Cancer Canada (PCC) is pleased to announce of the results of the recent Rising Star in Prostate Cancer Research competition. These awards provide salary and research support for outstanding research scientists initiating a career as independent investigators in prostate cancer research.

Each award is for three years starting January 1, 2014.

This opportunity is proudly funded by the Movember Foundation and Canada Safeway.

Movember Rising Stars in Prostate Cancer Research
Principal Investigator Institution Project Title Awarded Amount
Paul Boutros Ontario Institute for Cancer Research, Toronto, ON Discovering general features of prostate cancer biomarkers $450,000
Stanley Liu Sunnybrook Research Institute, Toronto, ON microRNA: elucidating their biology and significance in prostate cancer $450,000
Mathieu Lupien Princess Margaret Cancer Centre, Toronto, ON Identifying functional mutations in enhancers of prostate tumours $422,094
Frédéric Pouliot Université Laval, Quebec, QC Integrative prostate cancer detection and prognostication by molecular imaging $450,000
Safeway Rising Star in Prostate Cancer Research
Principal Investigator Institution Project Title Awarded Amount
Mads Daugaard Vancouver Prostate Centre, Vancouver, BC Targeting glycosaminoglycan structures in prostate cancer using recombinant parasite host-anchor proteins $450,000

Graduate Studentships in Prostate Cancer Recipients Announced

December 3, 2013 - Prostate Cancer Canada (PCC) is pleased to announce the results of the recent Graduate Studentships in Prostate Cancer competition. These awards provide a stipend for outstanding graduate students conducting prostate cancer research.

Each award is for one year starting January 1, 2014.

Awardee Award Name Project Title Awarded Amount
Peter Axerio-Cilies

University of British Columbia, Vancouver, BC
Steve Winter Graduate Studentship Award
 
Small peptide-mediated degradation of androgen receptor by targeting the N-terminal domain as a novel therapy for prostate cancer $40,000
Frédéric Couture

Université de Sherbrooke, Sherbrooke, QC
Edward Nash Graduate Studentship Award Validation of PACE4 potential for prostate cancer diagnosis $40,000
Kathleen DiSebastiano

University of Waterloo, Waterloo, ON
Constantine Karayannopoulos Graduate Studentship Award A comprehensive evaluation of glucose and lipid metabolism in high-risk prostate cancer patients throughout the disease trajectory: the relationship to body composition, nutrition, and physical activity $40,000
Philip Edgcumbe

University of British Columbia, Vancouver, BC
Amy and Donald McInnes Graduate Studentship Award Augmented reality elastography navigation aid for robotic assisted laparoscopic surgery $40,000
Mark Labrecque

Simon Fraser University, Burnaby, BC
Robert C Watson Graduate Studentship Award The role of Rb in HIF-mediated prostate cancer progression $40,000

Funding Decisions
PCC Spotlight
A Race Against Time: New prostate cancer research gives 24,000 Canadian men a fighting chance

TORONTO, ONTARIO, September 30, 2014:  Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. More

Prostate Cancer Canada Supports Innovation with Awarding of Movember Discovery Grants

Toronto, ON – Aug 14, 2014 – As part of our ongoing strategic commitment to prostate cancer research, Prostate Cancer Canada (PCC) is proud to announce the recipients of the 2014 Movember Discovery Grants, awarded by PCC, funded by Movember. More


Click here for news archive